(Filed after payment of issue fee)

### JC09 Rec'd PCT/PTO 2 6 SEP 2005

# IN THE UNITED STATES RECEIVING OFFICE (RO/US) Designated/Elected Office (DO/EO/US)

U.S. National Stage of International Application No.:		PCT/GB2004/001330					
International Filing Date:		26 March 2004					
Earlies	t Priority Date:	26 March 2003					
Applica	ants:	Peter David Davis, Matthew Alexander Naylor, Peter Thomson, Steven Albert Everett, Michael Richard Lacey Stratford, and Peter Wardman					
Title:		BIOREDUCTIVELY-ACTIVATED PRODRUGS					
Attorne	ey's Docket No.:	3963.1001-000					
		Date: <u>Ale September</u> 2008					
	EXPRESS MA	Date: <u>A6 Se<i>ptembel. 2006</i></u> IL LABEL NO. <u>EVA14887665US</u>					
	INFORM	1ATION DISCLOSURE STATEMENT					
	IN OIG	IN THE PROPERTY OF THE PROPERT					
Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450							
Sir:							
This Information Disclosure Statement is submitted:  [] under 37 CFR 1.129(a), or  (First/Second submission after Final Rejection)							
[X]		ds: three months of filing national application (other than a CPA) or date of entry of the n; or before the mailing date of a first office action on the merits in a non-provisional for Continued Examination).					
[]	under 37 CFR 1.97(c) together	er with either:					
	[ ] a Statement under 37 CFR 1.97(e), as checked below, or						
	$[ \ ]  a \ \$180.00 \ fee \ under \ 37 \ CFR \ 1.17(p), \ or \\ (\text{After the } 37 \ CFR \ 1.97(b) \ time period, but before final action or notice of allowance, whichever occurs first)$						
[]	under 37 CFR 1.97(d) togethe	er with:					
	[ ] a Statement under 37	CFR 1.97(e), as checked below, and					
	[ ] a \$180.00 fee under 3 (Filed after final action or notice of allowan	$7\ CFR\ 1.17(p)$ , or ce, whichever occurs first, but on or before payment of the issue fee)					
[]	under 37 CFR 1.97(i): Applicant requests that the III filewrapper.	OS and cited reference(s) be placed in the application					

[ ]

Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more

#### Statement Under 37 CFR 1.97(e)

- than three months prior to the filing of this Information Disclosure Statement; or No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. Statement Under 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, [ ] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. [X] Enclosed herewith is form PTO-1449: Copies of the cited references are enclosed. Copies of issued U.S. patents and published U.S. applications are not required and are not being provided. Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The
  - [X] The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
  - [ ] The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
    - [ ] the explanation provided on the attached sheet.

earlier application contains copies of the cited references.]

- the explanation provided in the Specification.
- [ ] submission of the enclosed International Search Report.
- [ ] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
- [ ] the enclosed English language abstract.

#### -3-

## JC09 Rec'd PCT/PTO 2 6 SEP 2005.

[]	Applicant requests that the following non-published pending applications be considered:								
Examiner's	;								
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]					
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]					
	-	U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]					
		Examiner	Date	-					
	[ ] A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.								
	[ ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.								
The E	xamine nces we	r is requested to return a copy of ere considered with the next offic	the above list of pending appe communication.	plications indicating which					
It is re	questec	I that the information disclosed h	erein be made of record in th	nis application.					
Metho	d of pa	yment:							
[ ]		A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.							
[]		Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.							
[X]	Please	charge any deficiency in fees an	d credit any overpayment to	Deposit Account 08-0380.					
		F	Respectfully submitted,						
		I	HAMILTON, BROOK, SMIT	ΓΗ & REYNOLDS, P.C.					
		E	sy WWD. CAM Alice O. Carroll	oll_					
Registration No. : 33,542 Telephone: (978) 341-0036 Facsimile: (978) 341-0136									

Concord, MA 01742-9133 Dated: September 26, 2005

# JC09 Rec'd PCT/PTO & 6 SEP 2005,

PTO-1449 REPRODUCED

### INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

ATTORNEY DOCKET NO.
3963.1001-000

FIRST NAMED INVENTOR
Peter David Davis

^107550864

FILING DATE 26 March 2004 (PCT)

September 26, 2005
(Use several sheets if necessary)

EXAMINER CONFIRMATION NO. GROUP

		F	OREIGN PATENT D	OCUMENTS		
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
J.L./	В1	WO 02/06279 A1	01-24-2002	Oxigene Inc.		
/J.L./	B2	WO 02/50007 A2	06-27-2002	Cancer Res. Ventures Ltd.		
/J.L./	В3	WO 2004/085361 A1	10-07-2004	Angiogene Pharm Ltd; Gray Lab. Cancer Research Trust		
	B4					
	B <b>8</b>					
	BS					
	B <b>8</b>					
	B8					
	B4					
	B10					
	Bl●					
	Bl●	,	•			
	B13					
	B14					
	B15					
	B14					
	B17					
	B18					
	B19					
	B20					
	B21					
	B22		·			
	B23					
	B24					

EXAMINER

/Jonathan Lau/

DATE CONSIDERED

05/15/2008